Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase

Virology

Volumn 484, Issue , 2015, Pages 354-363

  Colson, Philippe ^a,b   Borentain, Patrick ^a,b   Coso, Diane ^c   Motte, Anne ^a,b   Aurran Schleinitz, Therese ^c   Charbonnier, Aude ^c   Stoppa, Anne Marie ^c   Chabannon, Christian ^c   Serrero, Mélanie ^a   Bertrand, Julie ^a   Barlesi, Fabrice ^b   Serratrice, Jacques ^a   Portal, Isabelle ^a   Botta Fridlund, Daniele ^a   Tamalet, Catherine ^a,b   Gerolami, René ^a,b  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT PAOLI CALMETTES   (France)

Author keywords

Chemotherapy; HBsAg; HBV therapy; HBV DNA detection; Hepatitis B virus reactivation

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; TENOFOVIR DISOPROXIL; ANTINEOPLASTIC AGENT; MUTANT PROTEIN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIGEN STRUCTURE; ANTIGENIC VARIATION; ARTICLE; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CHRONIC HEPATITIS B; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B VIRUS; HUMAN; MALE; PRIORITY JOURNAL; SEROLOGY; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS RESISTANCE; VIRUS STRAIN; BLOOD; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; NEOPLASMS; PHYSIOLOGY; VIRUS ACTIVATION;

HEPATITIS B VIRUS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; MUTANT PROTEINS; NEOPLASMS; RNA-DIRECTED DNA POLYMERASE; VIRUS ACTIVATION;

EID: 84936994471     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.06.017     Document Type: Article

References (49)

1. Alavian S.M., Carman W.F., Jazayeri S.M. HBsAg variants: diagnostic-escape and diagnostic dilemma. J. Clin. Virol. 2013, 57(3):201-208.
2. Alexopoulou A., Theodorou M., Dourakis S.P., Karayiannis P., Sagkana E., Papanikolopoulos K., Archimandritis A.J. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations. J. Viral Hepat. 2006, 13(9):591-596.
3. Araujo N.M., Vianna C.O., Moraes M.T., Gomes S.A. Expression of Hepatitis B virus surface antigen (HBsAg) from genotypes A, D and F and influence of amino acid variations related or not to genotypes on HBsAg detection. Braz. J. Infect. Dis. 2009, 13(4):266-271.
4. Baclig M.O., Alvarez M.R., Gopez-Cervantes J., Natividad F.F. Unique surface gene variants of hepatitis B virus isolated from patients in the Philippines. J. Med. Virol. 2014, 86(2):209-216.
5. Borentain P., Colson P., Coso D., Bories E., Charbonnier A., Stoppa A.M., Auran T., Loundou A., Motte A., Ressiot E., Norguet E., Chabannon C., Bouabdallah R., Tamalet C., Gérolami R. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J. Viral Hepat. 2010, 17(11):807-815.
6. Carman W.F. The clinical significance of surface antigen variants of hepatitis B virus. J. Viral Hepat. 1997, 4(Suppl. 1):S11-S20.
7. Colson P., Borentain P., Motte A., Henry M., Moal V., Botta-Fridlund D., Tamalet C., Gérolami R. Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers. Virology 2007, 367(1):30-40.
8. Colson P., Borentain P., Coso D., Chabannon C., Tamalet C., Gérolami R. Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma. Br. J. Haematol. 2008, 143(1):148-150.
9. Cooreman M.P., Leroux-Roels G., Paulij W.P. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J. Biomed. Sci. 2001, 8(3):237-247.
10. European Association For The Study Of The Liver EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B Virus Infection. J. Hepatol. 2012, 57(1):167-185.
11. Ferraro D., Pizzillo P., Di Marco V., Vultaggio A., Iannitto E., Venezia G., Craxì A., Di Stefano R. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?. Liver Int. 2009, 29(8):1171-1177.
12. Gerlich W.H. Breakthrough of hepatitis B virus escape mutants after vaccination and virus reactivation. J. Clin. Virol. 2006, 36(Suppl. 1):S18-S22.
13. Gérolami R., Henry M., Borentain P., Colson P., Botta D., Tamalet C. Fulminant hepatitis B associated with a specific insertion in the basal core promoter region of hepatitis B virus DNA after immunosuppressive treatment. Clin. Infect. Dis. 2005, 40(4):e24-e27.
14. Gerolami R., Bourliere M., Colson P., Halfon P., Borentain P., Henry M., Botta D., Thibault V., Khiri H., Tamalet C. Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Antivir. Ther. 2006, 11(8):1103-1106.
15. Gérolami R., Borentain P., Colson P., Norguet E., Gérolami A., Tamalet C. Efficacy of hepatitis B virus (HBV) vaccination in treating lamivudine-resistant HBV reactivation following hepatitis B surface antigen seroconversion. Liver Int. 2007, 27(10):1417-1421.
16. Hsu C., Tsou H.H., Lin S.J., Wang M.C., Yao M., Hwang W.L., Kao W.Y., Chiu C.F., Lin S.F., Lin J., Chang C.S., Tien H.F., Liu T.W., Chen P.J., Cheng A.L. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2014, 59:2092-2100. Taiwan Cooperative Oncology Group.
17. Hwang J.P., Lok A.S. Management of patients with hepatitis B who require immunosuppressive therapy. Nat. Rev. Gastroenterol. Hepatol. 2014, 11:209-219.
18. Kim H.Y., Kim W. Chemotherapy-related reactivation of hepatitis B infection: updates in 2013. World J. Gastroenterol. 2014, 20:14581-14588.
19. Kim I.K., Kim B.G., Kim W., Kim D., Kim Y.J., Yoon J.H., Lee H.S. Clinical prediction of failure of lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy. Antimicrob. Agents Chemother. 2012, 56:5511-5519.
20. Kumar S., Tamura K., Nei M. MEGA: Molecular Evolutionary Genetics Analysis software for microcomputers. Comput. Appl. Biosci. 1994, 10(2):189-191.
21. Lalazar G., Rund D., Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br. J. Haematol. 2007, 136(5):699-712.
22. Lee S.Y., Choi M.S., Lee D., Lee J.H., Koh K.C., Paik S.W., Yoo B.C. Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy. J. Korean Med. Sci. 2005, 20(3):433-437.
23. Li H.R., Huang J.J., Guo H.Q., Zhang X., Xie Y., Zhu H.L., Zhai L.Z., Pu X.X., Huang Y., Guo C.C., Lin T.Y. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J. Viral Hepat. 2011, 18:877-883.
24. Lin C.L., Kao J.H. The clinical implications of hepatitis B virus genotype: recent advances. J. Gastroenterol. Hepatol. 2011, 26(Suppl. 1):S123-S130.
25. Lin X., Yuan Z.H., Wu L., Ding J.P., Wen Y.M. A single amino acid in the reverse transcriptase domain of hepatitis B virus affects virus replication efficiency. J. Virol. 2001, 75(23):11827-11833.
26. Lin Y.M., Jow G.M., Mu S.C., Chen B.F. Naturally occurring hepatitis B virus B-cell and T-cell epitope mutants in hepatitis B vaccinated children. Sci. World J. 2013, 26(2013):571875.
27. Ling W.H., Soe P.P., Pang A.S., Lee S.C. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br. J. Cancer 2013, 108(10):1931-1935.
28. Locarnini S., Bowden S. Drug resistance in antiviral therapy. Clin. Liver Dis. 2010, 14(3):439-459.
29. Malmström S., Eilard A., Larsson S.B., Hannoun C., Norkrans G., Lindh M. Genotype impact on long-term virological outcome of chronic hepatitis B virus infection. J. Clin. Virol. 2012, 54(4):321-326.
30. Mikulska M., Nicolini L., Signori A., Rivoli G., Del Bono V., Raiola A.M., Di Grazia C., Dominietto A., Varaldo R., Ghiso A., Bacigalupo A., Viscoli C. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogenic haematopoietic stem cell transplant recipients: risk factors and outcome. Clin. Microbiol. Infect. 2014, 20:694-701.
31. Moradi A., Zhand S., Ghaemi A., Javid N., Tabarraei A. Mutations in the S gene region of hepatitis B virus genotype D in Golestan Province-Iran. Virus Genes 2012, 44(3):382-387.
32. Nakamoto S., Kanda T., Nakaseko C., Sakaida E., Ohwada C., Takeuchi M., Takeda Y., Mimura N., Iseki T., Wu S., Arai M., Imazeki F., Saito K., Shirasawa H., Yokosuka O. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment. Int. J. Mol. Sci. 2014, 15:21455-21467.
33. Niscola P., Del Giudice M.I., Maurillo L., Solmone M., Capobianchi M.R., Carletti F., Piccioni D., Venditti A., Amadori S., Del Poeta G., Fulminant B. Hepatitis in a hepatitis B surface antigen-negative patient after rituximab therapy for B-CLL. Blood 2005, 106. (abst. 5025).
34. Ozasa A., Tanaka Y., Orito E., Sugiyama M., Kang J.H., Hige S., Kuramitsu T., Suzuki K., Tanaka E., Okada S., Tokita H., Asahina Y., Inoue K., Kakumu S., Okanoue T., Murawaki Y., Hino K., Onji M., Yatsuhashi H., Sakugawa H., Miyakawa Y., Ueda R., Mizokami M. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006, 44(2):326-334.
35. Pezzano S.C., Torres C., Fainboim H.A., Bouzas M.B., Schroder T., Giuliano S.F., Paz S., Alvarez E., Campos R.H., Mbayed V.A. Hepatitis B virus in Buenos Aires, Argentina: genotypes, virological characteristics and clinical outcomes. Clin. Microbiol. Infect. 2011, 17(2):223-231.
36. Sainokami S., Abe K., Sato A., Endo R., Takikawa Y., Suzuki K., Okamoto H. Initial load of hepatitis B virus (HBV), its changing profile, and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection. J. Gastroenterol. 2007, 42(3):241-249.
37. Salpini R., Colagrossi L., Bellocchi M.C., Surdo M., Becker C., Alteri C., Aragri M., Ricciardi A., Armenia D., Pollicita M., Di Santo F., Carioti L., Louzoun Y., Mastroianni C.M., Lichtner M., Paoloni M., Esposito M., D'Amore C., Marrone A., Marignani M., Sarrecchia C., Sarmati L., Andreoni M., Angelico M., Verheyen J., Perno C.F., Svicher V. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology 2015, 61(3):823-833.
38. Seto W.K., Chan T.S.Y., Hwang Y.Y., Wong D.K.H., Fung J., Liu K.S.H., Gill H., Lam Y.F., Lie A.K.W., Lai C.L., Kwong Y.L., Yuen M.F. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J. Clin. Oncol. 2014, 32:3736-3743.
39. Simon B., Kundi M., Puchhammer E. Analysis of mutations in the S gene of hepatitis B virus strains in patients with chronic infection by online bioinformatics tools. J. Clin. Microbiol. 2013, 51(1):163-168.
40. Sugauchi F., Tanaka Y., Kusumoto S., Matsuura K., Sugiyama M., Kurbanov F., Ueda R., Mizokami M. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J. Med. Virol. 2011, 83(3):412-418.
41. Tamalet C., Colson P., Henry M., Tourres C., Borentain P., Motte A., Gérolami.R. Molecular characterization of HBV genotypes newly diagnosed in 2004 in southern France. J. Clin. Virol. 2006, 36:S73.
42. Torresi J., Earnest-Silveira L., Civitico G., Walters T.E., Lewin S.R., Fyfe J., Locarnini S.A., Manns M., Trautwein C., Bock T.C. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002, 299(1):88-99.
43. Weinberger K.M., Bauer T., Böhm S., Jilg W. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J. Gen. Virol. 2000, 81(Pt 5):1165-1174.
44. Westhoff T.H., Jochimsen F., Schmittel A., Stoffler-Meilicke M., Schafer J.H., Zidek W., Gerlich W.H., Thiel E. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003, 102(5):1930.
45. Yao Q.Q., Dong X.L., Wang X.C., Ge S.X., Hu A.Q., Liu H.Y., Wang Y.A., Yuan Q., Zheng Y.J. Hepatitis B virus surface antigen (HBsAg)-positive and HBsAg-negative hepatitis B virus infection among mother-teenager pairs 13 years after neonatal hepatitis B virus vaccination. Clin. Vaccine Immunol. 2013, 20(2):269-275.
46. Yeo W., Zhong S., Chan P.K., Ho W.M., Wong H.T., Chan A.S., Johnson P.J. Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy. J. Viral Hepat. 2000, 7(6):448-458.
47. Yeo W., Chan T.C., Leung N.W., Lam W.Y., Mo F.K., Chu M.T., Chan H.L., Hui E.P., Lei K.I., Mok T.S., Chan P.K. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J. Clin. Oncol. 2009, 27(4):605-611.
48. Yong-Lin Y., Qiang F., Ming-Shun Z., Jie C., Gui-Ming M., Zu-Hu H., Xu-Bing C. Hepatitis B surface antigen variants in voluntary blood donors in Nanjing, China. Virol J. 2012, 9:82.
49. Zhang M., Gaschen B., Blay W., Foley B., Haigwood N., Kuiken C., Korber B. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 2004, 14(12):1229-1246.